Abstract
ICI D1694 is a quinazoline inhibitor of thymidylate synthase (TS) that was developed to act, at least in part, via metabolism to polyglutamate forms 1. The original rationale was based on the fact that CB3717, which was active in clinical studies, formed intracellular polyglutamates 2. These polyglutamates were ~ 100-fold better as inhibitors of TS and were not readily effluxed from the cell. Provided that the life-threatening and dose-limiting nephrotoxicity of CB3717 (see Clarke et al; this volume) was lost it was felt that a useful antitumour agent could be made. As the nephrotoxicity was thought to be due to the poor water-solubility of CB3717, particularly in acid urine, compounds with increased solubility were synthesised (see Clarke et al, this volume). Many of these compounds also had increased cytotoxicity but were generally poorer inhibitors of isolated TS and it was realised that a number of factors were responsible for these observations. Studies suggested that, unlike CB3717, many of the new analogues utilised the reduced-folate/MTX cell membrane transport carrier (RFC) which improved the rate of uptake and, for those that were substrates for folylpolyglutamate synthetase (FPGS), improved the rate of metabolism to polyglutamate forms (e.g. 2-desamino-2-methyl-N 10-propargyl-5,8-dideazafolate; ICI 198583)3’4. The combination of good transport via this carrier and very much improved FPGS substrate activity was a feature of a series of benzoyl ring modified quinazolines (5-membered rings) where the N 10-substituent was usually methyl 5. These compounds, although ~20-fold poorer than CB3717 as TS inhibitors were up to 500-fold more cytotoxic. In mice, improved potency over CB3717 was maintained by either single bolus or repeated once daily bolus administration (depending on the mouse model used, see Clarke et al, this volume) even though clearance of the compounds from the plasma was more rapid than CB3717 (βt1/2 of ~30 mins) 6 (unpublished observations; D.R. Newell and D.I. Jodrell).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A.L. Jackman, G.A. Taylor, W. Gibson, R. Kimbell, M. Brown, A.H. Calvert, I.R. Judson, and L.R. Hughes, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumour cell growth in vitro and in vivo: a new agent for clinical study, Cancer Res. 51: 5579 (1991).
E. Sikora, A.L. Jackman, D.R. Newell, and A.H. Calvert, Formation and retention and biological activity of N 10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro, Biochem. Pharmacol. 37: 4047 (1988).
A.L. Jackman, D.R. Newell, W. Gibson, D.I. Jodrell, G.A. Taylor, J.A. Bishop, L.R. Hughes, and A.H. Calvert, The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N 10-propargyl-5,8-dideazafolic acid (ICI 198583), Biochem. Pharmacol. 42: 1885 (1991).
A.L. Jackman, G.A. Taylor, B.M. O’Connor, J.A. Bishop, R.G. Moran, and A.H. Calvert, Activity of the thymidylate synthase inhibitor 2-desamino-N 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in vivo, Cancer Res. 50: 5212 (1990).
A.L. Jackman, P.R. Marsham, R.G. Moran, R. Kimbell, B.M. O’Connor, L.R. Hughes, and A.H. Calvert, Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N 10-substituted-5,8-dideazafolates, in: “Adv. Enz. Regul.”, G. Weber, ed; Pergamon Press, U.K. (1991).
A.L. Jackman, D.I. Jodrell, W. Gibson, and T.C. Stephens, ICI D1694 an inhibitor of thymidylate synthase for clinical study, in: “Purine and Pyrimidine Metabolism in Man V11, Part A”, R.A. Harkness et al, eds; Plenum Press, New York, pp 19–23 (1991).
G.B. Henderson, and E.M. Zevely, Transport of methotrexate in L1210 cells: effect of ions on the rate and extent of uptake, Arch. Biochem. Biophys. 200: 149 (1980).
W. Gibson, A.L. Jackman, G.M.F. Bisset, P.R. Marsham, and I.R. Judson, The measurement of 3 H ICI D1694 polyglutamate formation in L1210 cells in vitro by an HPLC ion-pairing method. Brit. J. Cancer, 6, Suppl. 8: 47 (1991).
D.W. Fry, J.A. Besserer, and T.J. Boritzki, Transport of the antitumour antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system, Cancer Res. 44: 3366 (1984).
A.L. Jackman, L.R. Kelland, M. Brown, W. Gibson, R. Kimbell, W. Aherne, and I.R. Judson, ICI D1694 resistant cell lines, Proc. Amer. Assoc. Cancer Res. 33: 406 (1992).
J.C. Yalowich and T.I. Kaiman, Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro, Biochem. Pharmacol. 34: 2319 (1985).
G.A. Taylor, A.L. Jackman, K. Balmanno, L.R. Hughes, and A.H. Calvert, estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase in whole cells, in: “Purine and Pyrimidine Metabolism in Man VI”, K, Mikanagi et al, eds; Plenum Press, New York, pp 383–388 (1989).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jackman, A.L., Gibson, W., Brown, M., Kimbell, R., Boyle, F.T. (1993). The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694. In: Rustum, Y.M. (eds) Novel Approaches to Selective Treatments of Human Solid Tumors. Advances in Experimental Medicine and Biology, vol 339. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2488-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2488-5_26
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6060-5
Online ISBN: 978-1-4615-2488-5
eBook Packages: Springer Book Archive